

(<http://aphanet.org>)

[Home](#) > Investigational cancer drug granted orphan status

---

**Generic Name:**

Amatuximab

**Trade Name:**

No trade name

**Company:**

Morphotek

**Notes:**

[Morphotek announced](#) that FDA has granted orphan drug designation to its investigational cancer drug amatuximab (MORAb-009) for the treatment of malignant pleural mesothelioma. Amatuximab is an investigational chimeric immunoglobulin G1 antibody that targets mesothelin, a cell surface glycoprotein which is over-expressed in a number of cancers. Morphotek noted that mesothelin is thought to be involved in cell adhesion and that its presence has been associated with a wide range of cancers such as pancreatic ductal adenocarcinoma, mesothelioma, epithelial ovarian cancer, and lung adenocarcinoma.

**Medication Monitor Categories:**

[New Drug Approvals](#)

**Use:**

Treatment of malignant pleural mesothelioma

---

**Source URL:** <http://aphanet.org/new-drug-approvals/investigational-cancer-drug-granted-orphan-status>